Michael Tenta

Palo Alto, Calif. – Cooley advised Versartis on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the Nasdaq Global Stock Market under the symbol "VSAR."

Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.

Cooley is advising FibroGen on its $167.7 million initial public offering. With a $1.04 billion valuation, this is the largest biotech IPO by market cap since 2002.

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer and other serious unmet medical needs. The company now trades on the Nasdaq Global Market under the symbol "FGEN."

Cooley advised Aduro Biotech on its $137 million initial public offering. Aduro is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company trades on the Nasdaq Global Market under the symbol "ADRO." Aduro also raised an additional $25 million in a private placement with Novartis Institutes for BioMedical Research, which closed concurrently with the offering.

Cooley is advising Eiger BioPharmaceuticals on its agreement to merge with publically-traded Celladon. Under the terms of the agreement, Eiger stockholders will become the majority owners of Celladon; the combined company will be called Eiger BioPharmaceuticals. The proposed merger is expected to close in the first half of 2016, subject to the approval of the stockholders of each company as well as regulatory approval and other customary conditions.

An investor syndicate has also committed to invest $39.5 million in the combined company upon closing of the merger. Cooley advised HBM Healthcare Investments, one of the investment firms joining existing longtime Eiger stockholders in the financing. The total cash balance of the combined company (upon its closing) and the financing is estimated at more than $60 million.

The merger will create a clinical-stage biopharma company with a diversified development portfolio of product candidates addressing novel targets for four orphan diseases: Hepatitis Delta Virus, bariatric surgery-induced hyperinsulinemic hypoglycemia, pulmonary arterial hypertension and lymphedema.

The Cooley team advising Eiger includes Glen Sato, Michael Tenta, Mark Windfeld-Hansen, Tali Sealman, Eric Batill, Peter Mandel, Laura Mouritsen, Bin Wang and Kristy Brady.

Carlton Fleming advised HBM.

Cooley advised Sonim Technologies on its $39.3 million initial public offering of 3,571,429 shares of common stock. Jon Gavenman and Mike Tenta led the Cooley team advising Sonim Technologies.

Oppenheimer acted as lead book-running manager and Lake Street Capital Markets acted as joint book-running manager for the offering. National Securities Corporation acted as co-manager for the offering.

Sonim is a leading U.S. provider of ultra-rugged mobility solutions designed specifically for task workers physically engaged in their work environments. The company’s shares now trade on the Nasdaq Global Market under the symbol “SONM.”